https://scholar.korea.ac.kr/handle/2021.sw.korea/2553 2026-04-05T15:38:11Z https://scholar.korea.ac.kr/handle/2021.sw.korea/270710 Title: National trends in dyslipidemia prevalence, awareness, treatment, and control in South Korea from 2005 to 2022 Authors: Lee, Hyeseung; Kim, Seokjun; Son, Yejun; Kim, Soeun; Kim, Hyeon Jin; Jo, Hyesu; Park, Jaeyu; Lee, Kyeongmin; Lee, Hayeon; Kang, Jiseung; Woo, Selin; Kim, Sunyoung; Rhee, Sang Youl; Hwang, Jiyoung; Smith, Lee; Yon, Dong Keon Abstract: Dyslipidemia has steadily increased in South Korea over the past two decades, emerging as a major public health concern and key risk factor for cardiovascular disease. Thus, our study aimed to investigate long-term trends in the prevalence, awareness, treatment, and control of dyslipidemia in South Korea, including the COVID-19 pandemic. This study utilized data from nationally representative cross-sectional surveys conducted as part of the Korea National Health and Nutrition Examination Survey from 2005 to 2022, analyzing long-term trends of dyslipidemia among 98,396 individuals aged over 30. Weighted linear and binary logistic regression were performed to calculate the beta coefficients, beta diff, and weighted odds ratios with 95% confidence intervals (CIs). Weighted odds ratios were computed for various socioeconomic groups using aggregated data from 2005 to 2022. The prevalence of dyslipidemia increased from 41.30% (95% CI 40.40-42.21) in 2005-2009 to 48.41% (47.36-49.47) in 2020-2022. Awareness increased from 17.87% (16.75-18.99) to 48.90% (47.34-50.47), treatment from 7.10% (6.39-7.80) to 38.19% (36.61-39.76), and control among prevalence from 6.49% (5.79-7.19) to 31.82% (30.33-33.32). Treatment (beta diff, 3.94 [1.97-5.92]) and control among prevalence (beta diff, 3.52 [1.67-5.38]) increased more rapidly during the pandemic. Higher odds of dyslipidemia were associated with male sex, older population, rural residence, high BMI, central adiposity, low education and income levels, smoking, and high-risk alcohol consumption. Lower odds of awareness, treatment, and control among individuals with dyslipidemia were associated with male sex, younger population, rural residence, higher education and income levels, smoking, and high-risk alcohol consumption. Over the past 18 years, the prevalence, awareness, treatment, and control of dyslipidemia have steadily increased, with persistent disparities among socioeconomic groups. 2025-05-09T00:00:00Z https://scholar.korea.ac.kr/handle/2021.sw.korea/269503 Title: Per- and polyfluoroalkyl substances exposures are associated with non-alcoholic fatty liver disease, particularly fibrosis Authors: Hwang, Se-Hyun; Choi, Yun-Hee; Huh, Da-An; Kim, Lita; Park, Kangyeon; Lee, Jiyoun; Choi, Hyeon Jeong; Lim, Woohyun; Moon, Kyong Whan Abstract: Per- and polyfluoroalkyl substances (PFAS) have been reported to exert hepatotoxic effects; however, their impact on nonalcoholic fatty liver disease (NAFLD) remains unclear. This study aimed to investigate the association between PFAS exposure and NAFLD in Korean adults, thereby contributing to the generalization of PFAS's hepatotoxic effects. Using data from the 2018-2020 Korean National Environmental Health Survey (KoNEHS), we analyzed 2635 Korean adults. PFAS exposure levels were estimated based on the serum concentrations of five PFAS. NAFLD was assessed using two steatosis-related indices (hepatic steatosis index [HSI] and fatty liver index [FLI]) and two fibrosis-related indices (fibrosis-4 index [FIB-4] and aspartate aminotransferase to platelet ratio index [APRI]). The models included these indices as continuous and dichotomous variables, the latter based on diagnostic criteria from previous studies. Associations with PFAS exposure were examined using multiple linear regression and robust Poisson regression models. Positive associations were observed between PFAS exposure and three of the four continuous indices, excluding the FLI, as well as the prevalence of NAFLD diagnosed using these indices. Specifically, the HSI showed a significant association only with perfluorononanoic acid, whereas fibrosis-related indices (FIB-4 and APRI) were significantly associated with all five individual PFAS. The associations were stronger in female and non-obese groups when stratified by sex and obesity status. The results of the Bayesian kernel machine regression analysis evaluating the health effects of PFAS mixtures indicated an association between PFAS mixtures and NAFLD, particularly fibrosis-related indices. Additionally, significant associations with NAFLD indices were mostly observed in females and non-obese groups, supporting the findings from the individual PFAS exposure analyses. Our findings suggest that PFAS are associated with NAFLD, particularly for fibrosis. Considering the high serum PFAS concentrations in the Korean population, continuous monitoring and prospective cohort studies are warranted. 2025-05-01T00:00:00Z https://scholar.korea.ac.kr/handle/2021.sw.korea/270727 Title: Postacute Sequelae of COVID-19 Across 12 Major Health Domains and 141 Diseases in Individuals With Mental Illness Among COVID-19 Survivors: A Population-Based Cohort Study in South Korea Authors: Kang, Jiseung; Park, Jaeyu; Son, Yejun; Kim, Hyeon Jin; Fond, Guillaume; Boyer, Laurent; Rahmati, Masoud; Lee, Hayeon; Yon, Dong Keon Abstract: Understanding whether individuals with mental illness, who face challenges related to healthcare barriers, are more vulnerable to postacute sequelae of COVID-19 is limited. Here, we investigated the potential association between pre-existing mental illness and postacute sequelae of COVID-19 across 12 major health domains and 141 specific diseases in COVID-19 survivors. The large-scale, population-based cohorts from South Korea (K-COV-N cohort) used in the study included 8 632 221 individuals aged 20 years or older who were infected with SARS-CoV-2 between January 1, 2020, and December 31, 2022. The risk of postacute sequelae of COVID-19 was assessed in the 1:2 propensity score-matched cohorts, comprising 12 major health domains and 141 diseases based on the ICD-10 code, following mental illness among patients with COVID-19. We assessed the time attenuation effect of major health outcomes after 30 days following SARS-CoV-2 infection. Multiple subgroup analyses were conducted by severity of mental illness, COVID-19 severity, vaccination, and SARS-CoV-2 strain. After 1:2 exposure-driven propensity score matching, we identified 1 341 320 participants with mental illness (mean age, 49.51 [SD, 13.82] years; 62.27% female) and 2 653 597 controls (mean age, 48.78 [SD, 13.75] years; 62.03% female). Individuals with mental illness exhibited significantly higher risks across all 12 major health domains, including: infectious and parasitic events (adjusted hazard ratio [aHR], 1.36 [95% CI, 1.33-1.38]), blood and immune-related events (1.21 [1.17-1.26]), endocrine, nutritional, and metabolic events (1.21 [1.18-1.24]), nerve-related events (2.13 [2.07-2.19]), eye-related events (1.29 [1.25-1.34]), ear and mastoid events (1.52 [1.50-1.54]), circulatory events (1.25 [1.17-1.35]), respiratory events (1.26 [1.24-1.29]), digestive events (1.41 [1.40-1.41]), skin-related events (1.34 [1.30-1.38]), musculoskeletal events (1.42 [1.41-1.43]), and genitourinary events (1.54 [1.18-2.01]). Of the 141 postacute sequelae of COVID-19, 133 showed significantly increased risks. The association was strongest within the first 6-12 months after SARS-CoV-2 infection, with risks progressively attenuating beyond 12 months and nearly disappearing after 18 months. Subgroup analysis revealed that individuals with mild mental illness exhibited higher aHRs for 11 of the 12 health outcome domains compared with those with severe mental illness. Altogether, our findings show the increased risk of postacute sequelae of COVID-19 across 12 major health domains in individuals with mental illness among COVID-19 survivors. These findings highlight the need for targeted monitoring and intervention strategies to address the vulnerabilities of this population, particularly during the post-COVID-19 period. 2025-05-01T00:00:00Z https://scholar.korea.ac.kr/handle/2021.sw.korea/269348 Title: Global and regional estimates of vaccine-associated herpes zoster and their related vaccines from 1969 to 2023 Authors: Jeong, Jinyoung; Jo, Hyesu; Son, Yejun; Park, Jaeyu; Oh, Jiyeon; Lee, Sooji; Jeong, Yi Deun; Lee, Kyeongmin; Kim, Hyeon Jin; Lee, Hayeon; Kim, Soeun; Yim, Yesol; Rahmati, Masoud; Kang, Jiseung; Udeh, Raphael; Pizzol, Damiano; Smith, Lee; Hwang, Jiyoung; Yon, Dong Keon Abstract: Vaccine-induced immunosuppression can reactivate the varicella-zoster virus, potentially leading to the development of herpes zoster. However, the literature on this topic is inconsistent, resulting in limited clarity. Therefore, we aimed to enhance our understanding of vaccine-associated herpes zoster and establish guidelines for future research, utilizing a global database to improve global public health. We investigated vaccine-associated adverse events in herpes zoster using reports (similar to 13 million reports) from the WHO international pharmacovigilance database. Data were analyzed for the global number of reports, reported odds ratios (ROR), and information components (IC) to determine the potential association between 18 vaccines and vaccine-associated herpes zoster reports in nearly 170 countries and territories from 1969 to 2023. Of 7,805,380 vaccine-associated adverse events, there were 51,985 herpes zoster reports. Vaccine-associated herpes zoster showed the highest strength of association with COVID-19 mRNA vaccines (ROR, 11.85 [95% CI, 11.70-12.01]; IC, 2.74 [IC0.25, 2.72]), followed by encephalitis (ROR, 4.07 [95% CI, 3.37-4.92]; IC, 2.00 [IC0.25, 1.68]), influenza (ROR, 3.44 [95% CI, 3.28-3.62]; IC, 1.77 [IC0.25, 1.69]), and ad5-vectored COVID-19 vaccines (ROR, 3.05 [95% CI, 2.97-3.14]; IC, 1.54 [IC0.25, 1.50]). The ROR and IC of vaccine-associated herpes zoster in males (ROR, 7.94 [95% CI, 7.80-8.08]; IC, 2.47 [IC0.25, 2.45]) and females (ROR, 6.71 [95% CI, 6.62-6.80]; IC, 2.30 [IC0.25, 2.28]). The ROR and IC increased with advancing age. Our findings emphasize the need to consider the immune status of vaccine recipients and to implement appropriate compensation and management manuals for vaccine-associated herpes zoster. 2025-04-17T00:00:00Z